Du är här

2015-10-09

Abiomed: Abiomed Second Quarter Fiscal 2016 Earnings and Conference Call Notification

DANVERS, Mass., Oct. 08, 2015 (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ:ABMD)
announced today that on Thursday, October 29, 2015, the Company will release
financial results for the second quarter of fiscal 2016. The Company will
host a conference call to discuss the results on Thursday, October 29, 2015,
at 8:00 a.m. EDT. Michael R. Minogue, Chairman, President and Chief Executive
Officer; Michael Tomsicek, Vice President and Chief Financial Officer, will
host the conference call.

To listen to the call live, please tune into the webcast via
http://investor.abiomed.com or dial (855) 212-2361; the international number
is (678) 809-1538. A replay of this conference call will be available
beginning at 11 a.m. EDT October 29, 2015 through 11:59 p.m. EDT on October
31, 2015. The replay phone number is (855) 859-2056; the international number
is (404) 537-3406. The replay access code is 55643535.

ABOUT ABIOMED

Based in Danvers, Massachusetts, Abiomed, Inc., is a leading provider of
medical devices that provide circulatory support. Our products are designed
to enable the heart to rest by improving blood flow and/or performing the
pumping of the heart. For additional information please visit:
www.abiomed.com

FORWARD-LOOKING STATEMENTS

This release contains forward-looking statements, including statements
regarding development of Abiomed's existing and new products, the Company's
progress toward commercial growth, and future opportunities and expected
regulatory approvals. The Company's actual results may differ materially from
those anticipated in these forward-looking statements based upon a number of
factors, including uncertainties associated with development, testing and
related regulatory approvals, including the potential for future losses,
complex manufacturing, high quality requirements, dependence on limited
sources of supply, competition, technological change, government regulation,
litigation matters, future capital needs and uncertainty of additional
financing, and other risks and challenges detailed in the Company's filings
with the Securities and Exchange Commission, including the most recently
filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q. Readers
are cautioned not to place undue reliance on any forward-looking statements,
which speak only as of the date of this release. The Company undertakes no
obligation to publicly release the results of any revisions to these
forward-looking statements that may be made to reflect events or
circumstances that occur after the date of this release or to reflect the
occurrence of unanticipated events.

For further information please contact:
Ingrid Goldberg
Director, Investor Relations
978-646-1590
igoldberg@abiomed.com

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Abiomed via Globenewswire

HUG#1957961

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.